Seòmar agus comataidhean

The Scottish Fire and Rescue Service (SFRS) has 456 rescue pump appliances in operation. 211 of these are more than 15 years old, however all SFRS appliances are properly maintained to ensure they remain fully operational, and the oldest vehicles are placed in locations where they will be least used.

The Scottish Government has increased the Scottish Fire and Rescue Service (SFRS) capital budget by £10.5 million in 2024-25 and by a further £4 million in 2025-26, bringing the total annual budget to £47 million. SFRS is currently conducting a Service Delivery Review to ensure that investment in its estate, fleet and equipment is focussed where it is needed most.

The Penrose Inquiry’s report, published on 25 March 2015, contained a single recommendation, which was that the Scottish Government take all reasonable steps to offer a hepatitis C virus (HCV) test to everyone in Scotland who had a blood transfusion before September 1991 and who has not been tested for HCV. The Scottish Government accepted this recommendation and in response a Short-Life Working Group (SLWG), involving key stakeholders such as the Scottish National Blood Transfusion Service, was established by Health Protection Scotland. The SLWG progress report was published on 2 September 2016, setting out the range of work undertaken by the SLWG.

The Scottish Government accepted the recommendation of the SLWG that there should be an awareness raising campaign to encourage people who had (or are likely to have had) a blood transfusion prior to 1991, and who have not already been tested for hepatitis C, to come forward for testing. A targeted awareness raising campaign to encourage such individuals to be tested was launched in October 2016 and an evaluation of the campaign, as recommended by the SLWG, was completed by Health Protection Scotland in 2018. The SLWG also recommended that a Chief Medical Officer letter should be sent to all clinicians in Scotland to remind them of certain risk factors and clinical indicators for HCV infection and making them aware of the recent advances in therapy and thus the benefits of HCV testing. The Chief Medical Officer accordingly wrote to all clinicians in Scotland on 20 September 2016, following up a previous letter issued just after the publication of the Penrose report on 27 March 2015. The Penrose Inquiry’s recommendation has therefore been fully implemented.

Scottish Government committed to a Four Day Working Week pilot in the public sector to explore the wellbeing and productivity benefits that a shorter working week could bring. No additional funding was allocated to either Accountancy in Bankruptcy or South of Scotland Enterprise to deliver the pilot in their organisations.

The pilot was delivered in partnership with The Autonomy Institute who published their evaluation report on 27 August. The report can be accessed here - Four day working week pilot - Public sector pay - gov.scot.

We recognise the challenges facing Scotland’s health and social care system. That is why we have already taken significant steps to set out clear, short and longer term actions to improve access to treatment, shift the balance of care, harness digital innovation, and strengthen prevention.

We recently published the, Foreword - NHS Scotland operational improvement plan - gov.scot the Scotland's Population Health Framework - gov.scot and the Health and Social Care Service Renewal Framework - gov.scot in which we outline our shared vision for reforming and renewing health and social care services to ensure they are more sustainable, preventative, and equitable.

We remain committed to engaging with leaders across health and social care, including clinical leaders, to design and deliver the change needed in our NHS.

With regard to charging for services, the Scottish Government’s policy could not be clearer: our National Health Service must be maintained on its founding principles – publicly owned, publicly operated, and free at the point of need. As we have previously said, the provision of health services must always be based on the individual needs of a patient.

The Scottish Government is committed to improving life expectancy and tackling health inequalities across Scotland. The recently published Population Health Framework, a joint publication by the Scottish Government and COSLA, highlights that the circumstances and environments in which people are born, grow up, live, work and age – known as the building blocks of health – are the most influential factors shaping health outcomes.

The Framework’s supporting evidence paper notes that Scotland has experienced a decline in healthy life expectancy – the number of years people can expect to live in good health – alongside a stalling of improvements in mortality rates after decades of steady progress. These trends are associated with several major factors: the UK Government’s austerity policies during the 2010s, Brexit, the COVID-19 pandemic, and the ongoing cost-of-living crisis. Together, these influences have weakened the building blocks of health, widened existing inequalities, and exacerbated Scotland’s longstanding disparities in income, wealth, and power.

In response, the Population Health Framework sets out a whole-system cross-government and cross-sector approach centred on prevention. This approach builds on existing Scottish Government actions, including initiatives on diet and healthy weight, and efforts to tackle child poverty. Through this approach, the Scottish Government aims to raise overall life expectancy while closing the gap between the most deprived 20% of communities and the national average by 2035.

Whilst Scottish Government sets the strategic policy direction for the NHS in Scotland, operational matters including staffing are the responsibility NHS Boards. NHS Boards take account of national, regional, and local priorities, and we expect NHS boards to plan and provide safe, effective, and high-quality care, in line with their statutory service provision and workforce planning responsibilities.

To help address recognised workforce pressures, Scottish Government continues to invest heavily in radiology training. Scottish Government is currently funding around 190 specialty training places in clinical radiology, including 78 extra places which have been added since 2014. This enables doctors to train and enter the workforce following completion of training - which takes a minimum of 5 years. Clinical radiology specialty training programmes have been filled at 100% in Scotland from 2014 to 2024, with 230 resident doctors successfully completing training in this period.

To further support a coordinated response to pressures in cancer services, Scottish Government commissioned the National Oncology Coordination Group. This group considers real-time assessments and develops proactive risk mitigation proposals aligned with the strategic aims for cancer. This collaborative approach across NHS Boards in Scotland is ensuring that services can deliver for people with cancer.

The Scottish Government is committed to increasing the availability of safe and effective medicines that people in Scotland would benefit from. The Scottish Medicines Consortium (SMC) assesses the clinical and cost effectiveness of newly licensed medicines on a once for Scotland basis and publishes advice for Health Boards to consider. It is expected that Health Board Area & Drug and Therapeutics Committees (ADTCs) will consider making an SMC recommended medicine, or an equivalent, available on their local or regional formulary for routine prescribing within 90 days of SMC advice being published.

Health Boards are expected to apply common principles and processes in the introduction of newly licensed medicines to facilitate consistency of approach to local decision-making. The decision to prescribe a medicine, and which medicine to prescribe, is entirely for the clinician in charge of a person’s care, having considered their clinical condition, their safety, and any relevant clinical guidance.

I wrote to Ashley Dalton MP, Parliamentary Under-Secretary of State for Public Health and Prevention at the Department for Health & Social Care (DHSC) on 8 Aprill 2025 in order to outline the Scottish Government’s position on Clauses 2 and 3 of the Rare Cancers Bill.

Over the last year, my officials have been engaging in active conversation with the UK Government and the other devolved nations on the implementation of the provisions of the Bill.

Vorasidenib (Voranigo®) does not currently have a marketing authorisation (sometimes referred to as a licence) from the Medicines and Healthcare products Regulatory Agency (MHRA) which means it cannot be marketed or sold in the UK. The marketing authorisation process involves the MHRA reviewing and assessing the evidence supporting a medicinal product’s quality, safety and efficacy.

As a result, vorasidenib is being offered for a limited time by the pharmaceutical company, Servier, through a free-of-charge (FOC) pharmaceutical company-led early access programme. Health Boards have processes for considering the use of an unlicensed medicine, including through FOC early access programmes, on an individual case-by-case basis where the clinician feels it would benefit an individual. The Scottish Government does not hold data on these decisions.

Individual Health Boards are responsible for decisions on the implementation and availability of medicines in their area. The Scottish Government has committed to investing rebates from the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) to fund the New Medicines Fund (NMF), which provides additional top-up funding to territorial Health Boards to support the cost of introducing new medicines. Since 2014/15, £906 million has been made available to Health Boards via the NMF.